Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1990 2
1991 15
1992 20
1993 28
1994 35
1995 119
1996 89
1997 114
1998 121
1999 116
2000 118
2001 149
2002 179
2003 128
2004 133
2005 161
2006 116
2007 118
2008 116
2009 121
2010 125
2011 127
2012 110
2013 125
2014 108
2015 100
2016 108
2017 93
2018 95
2019 113
2020 100
2021 89
2022 106
2023 99
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

3,279 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 103577-45-3
Page 1
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Laine L, et al. Gastroenterology. 2023 Jan;164(1):61-71. doi: 10.1053/j.gastro.2022.09.041. Epub 2022 Oct 10. Gastroenterology. 2023. PMID: 36228734 Free article. Clinical Trial.
METHODS: Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks. Patients with healing were rerandomized to once-daily vonoprazan, 10 mg, vonoprazan, 20 mg, or lansoprazole, 15 mg, for 24 weeks. ... …
METHODS: Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks. …
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Chey WD, et al. Gastroenterology. 2022 Sep;163(3):608-619. doi: 10.1053/j.gastro.2022.05.055. Epub 2022 Jun 6. Gastroenterology. 2022. PMID: 35679950 Free article. Clinical Trial.

Eradication rates in clarithromycin-resistant infections: vonoprazan triple therapy 65.8%, dual therapy 69.6%, vs lansoprazole triple therapy 31.9% (both superior; difference 33.9%; 95% CI, 17.7-48.1; P < .001; difference 37.7%; 95% CI, 20.5-52.6; P < .001, respectiv

…
Eradication rates in clarithromycin-resistant infections: vonoprazan triple therapy 65.8%, dual therapy 69.6%, vs lansoprazole triple …
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E, Toumi H. Lespessailles E, et al. Int J Mol Sci. 2022 Sep 14;23(18):10733. doi: 10.3390/ijms231810733. Int J Mol Sci. 2022. PMID: 36142643 Free PMC article. Review.
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). Recently, the risks and benefits of long-term PPI use were questioned and many studies indicated that their use should …
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazo …
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K, Kinoshita Y, Yao T, Kushima R, Akiyama J, Aoyama N, Kanoo T, Miyata K, Kusumoto N, Uemura N. Haruma K, et al. BMC Gastroenterol. 2023 May 1;23(1):139. doi: 10.1186/s12876-023-02772-w. BMC Gastroenterol. 2023. PMID: 37127558 Free PMC article. Clinical Trial.
RESULTS: Of 208 patients (vonoprazan, n = 139; lansoprazole, n = 69) entering the healing phase, 202 entered the maintenance phase (vonoprazan, n = 135; lansoprazole, n = 67). At 3 years, 109 vonoprazan-treated and 58 lansoprazole-treated patients remained on …
RESULTS: Of 208 patients (vonoprazan, n = 139; lansoprazole, n = 69) entering the healing phase, 202 entered the maintenance phase (v …
Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole.
Bai AD, Wilkinson A, Almufleh A, Rai M, Razak F, Verma AA, Srivastava S. Bai AD, et al. JAMA Netw Open. 2023 Oct 2;6(10):e2339893. doi: 10.1001/jamanetworkopen.2023.39893. JAMA Netw Open. 2023. PMID: 37883084 Free PMC article.
IMPORTANCE: The combination of ceftriaxone and lansoprazole has been shown to prolong the corrected QT interval on electrocardiogram. ...EXPOSURE: Lansoprazole during ceftriaxone treatment vs other PPIs during ceftriaxone treatment. ...
IMPORTANCE: The combination of ceftriaxone and lansoprazole has been shown to prolong the corrected QT interval on electrocardiogram. …
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, Moon JS, Lim YJ, Kang DH, Cheon GJ, Baik GH, Kim KO, Cho KB, Jang JS, Park JJ, Son BK, Jung HK, Kim BW, Kim SK, Lee ST, Cha JM, Kim AR, Kim EJ, Park HW, Song GS. Cho YK, et al. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865. Epub 2020 Jul 23. Aliment Pharmacol Ther. 2020. PMID: 32701188 Free PMC article. Clinical Trial.
In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 we …
In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg a …
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL, Lin BS, Li YY, Ding YM, Han ZX, Ji R. Zhang WL, et al. Digestion. 2023;104(4):249-261. doi: 10.1159/000529622. Epub 2023 Apr 4. Digestion. 2023. PMID: 37015201 Free PMC article.
The efficacy of vonoprazan/amoxicillin dual therapy was not inferior to that of triple therapy with pooled risk ratio (RR) of 1.03 (95% CI: 0.97-1.10) and 1.02 (95% CI: 0.98-1.08) in intention-to-treat and per-protocol analyses; while it was significantly superior to the omeprazo …
The efficacy of vonoprazan/amoxicillin dual therapy was not inferior to that of triple therapy with pooled risk ratio (RR) of 1.03 (95% CI: …
Reply.
Nieves JW, Perez MC, Metz DC, Hansen KE. Nieves JW, et al. Gastroenterology. 2019 Aug;157(2):586. doi: 10.1053/j.gastro.2019.06.006. Epub 2019 Jun 13. Gastroenterology. 2019. PMID: 31260666 No abstract available.
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, Sheu BS, Chong CF, Funao N, Zhou W, Chen M. Xiao Y, et al. Gut. 2020 Feb;69(2):224-230. doi: 10.1136/gutjnl-2019-318365. Epub 2019 Aug 13. Gut. 2020. PMID: 31409606 Free PMC article. Clinical Trial.
OBJECTIVE: To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO). ...Overall, EO healing rates appeared higher with vonoprazan versus lansoprazole. TEAE rates were 38.1% and 36.6% i …
OBJECTIVE: To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive o …
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K. Ashida K, et al. Aliment Pharmacol Ther. 2016 Jan;43(2):240-51. doi: 10.1111/apt.13461. Epub 2015 Nov 11. Aliment Pharmacol Ther. 2016. PMID: 26559637 Free PMC article. Clinical Trial.

The proportion of patients with healed EE up to week 8 was 99.0% for vonoprazan (203/205) and 95.5% for lansoprazole (190/199), thus verifying the non-inferiority of vonoprazan (P < 0.0001). ...Overall, vonoprazan was well-tolerated. CONCLUSIONS: The non-inferiority of

…
The proportion of patients with healed EE up to week 8 was 99.0% for vonoprazan (203/205) and 95.5% for lansoprazole (190/199), thus …
3,279 results